文献速递肝病

肝纤维化:从机制到药物靶向过氧化物酶体增殖物激活受体α

Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
PubMed 文献 · Hepatology · 2023-01-03

肝纤维化是慢性肝损伤和炎症导致肝细胞死亡及纤维瘢痕形成的后果,是NASH和酒精性脂肪性肝炎的标志,可进展为肝硬化、肝细胞癌和肝衰竭。临床前研究表明,过氧化物酶体增殖物激活受体α(PPARα)通过激活解毒脂毒性和毒素相关基因、反式抑制炎症相关基因及抑制肝星状细胞活化,在预防肝纤维化中起重要作用。基于这些稳健的临床前数据,多种PPARα激动剂已在肝纤维化临床试验中测试。本文综述了PPARα预防纤维化机制的最新进展,并讨论了靶向PPARα开发抗纤维化治疗的潜力。

要点

  • 肝纤维化是NASH和酒精性脂肪性肝炎的标志,可导致肝硬化、肝细胞癌和肝衰竭。
  • PPARα通过激活解毒基因、反式抑制炎症基因和抑制肝星状细胞活化来预防肝纤维化。
  • 基于临床前数据,多种PPARα激动剂已在肝纤维化临床试验中测试。

核心结论

  • 临床前研究提示PPARα在预防肝纤维化中起重要作用,靶向PPARα有望开发抗纤维化治疗。

研究设计与样本

  • 综述:总结PPARα预防纤维化机制的最新进展及PPARα激动剂在肝纤维化临床试验中的测试情况。

主要发现

  • 肝纤维化是持续慢性肝损伤和炎症导致肝细胞死亡及纤维瘢痕形成的结果,是NASH和酒精性脂肪性肝炎的标志。
  • PPARα通过激活解毒脂毒性和毒素相关基因、反式抑制炎症相关基因及抑制肝星状细胞活化来预防肝纤维化。
  • 基于稳健的临床前数据,多种PPARα激动剂已在肝纤维化临床试验中测试。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver fibrosis is the result of sustained chronic liver injury and inflammation leading to hepatocyte cell death followed by the formation of fibrous scars, which is the hallmark of NASH and alcoholic steatohepatitis and can lead to cirrhosis, HCC, and liver failure. Although progress has been made in understanding the pathogenesis and clinical consequences of hepatic fibrosis, therapeutic strategies for this disease are limited. Preclinical studies suggest that peroxisome proliferator-activated receptor alpha plays an important role in preventing the development of liver fibrosis by activating genes involved in detoxifying lipotoxicity and toxins, transrepressing genes involved in inflammation, and inhibiting activation of hepatic stellate cells. Given the robust preclinical data, several peroxisome proliferator-activated receptor alpha agonists have been tested in clinical trials for liver fibrosis. Here, we provide an update on recent progress in understanding the mechanisms by which peroxisome proliferator-activated receptor alpha prevents fibrosis and discuss the potential of targeting PPARα for the development of antifibrotic treatments.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gong L, Wei F, Gonzalez FJ, et al. Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology. 2023. PMID: 36626642. doi:10.1097/HEP.0000000000000182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。